|drug2878||SARS-CoV-2 rS - Phase 1 Wiki||1.00|
|drug2881||SARS-CoV-2 rS/Matrix-M Adjuvant - Phase 1 Wiki||1.00|
|drug2882||SARS-CoV-2 rS/Matrix-M Adjuvant, Day 0 - Phase 1 Wiki||1.00|
|drug2880||SARS-CoV-2 rS/Matrix-M Adjuvant - Day 189 - Phase 2 Wiki||1.00|
|drug2883||SARS-CoV-2 rS/Matrix-M Adjuvant, Day 0 - Phase 2 Wiki||1.00|
|drug2216||Normal saline solution (NSS), Placebo, Day 189 - Phase 2 Wiki||1.00|
|drug2215||Normal saline solution (NSS), Placebo - Phase 2 Wiki||1.00|
|drug2884||SARS-CoV-2 rS/Matrix-M Adjuvant, Days 0 and 21 - Phase 2 Wiki||1.00|
|drug2214||Normal saline solution (NSS), Placebo - Phase 1 Wiki||1.00|
|drug2217||Normal saline solution (NSS), Placebo, Day 21 - Phase 1 Wiki||1.00|
|drug2218||Normal saline solution (NSS), Placebo, Day 21 - Phase 2 Wiki||1.00|
|D045169||Severe Acute Respiratory Syndrome NIH||0.04|
|D018352||Coronavirus Infections NIH||0.04|
There is one clinical trial.
The purpose of this study is to assess the safety and efficiency of an assembled modified mask in protecting health care workers against Coronavirus in case of any personal protective equipment shortage. At least 20 healthy participants will be recruited to try the modified mask. The modified masks will be made from masks that are already available as well as filters available in the pulmonary department at the Oklahoma City VA Health Care System
Description: Conduct a quantitative fit test and calculate the percentage of participants who pass the test.Measure: Success Percentage Time: 15 minutes
Description: Change in end-tidal CO2 from 0 to 15 minutes while wearing the Full or the Whole maskMeasure: End-tidal CO2 Variation. Description: mmHg. Time: at 0 and 15 minutes
Description: Measure the change in Oxygen Pulse Oximetry from 0 to15 minutes while wearing the Full or the Whole maskMeasure: Oxygen Pulse Oximetry Variation. Description: mmHg. Time: at 0 and 15 minutes.
Description: Evaluate the visibility (5-point Likert scale from Absent to Complete) while wearing the Full or the Whole mask for 15 minutesMeasure: Mask Visibility. Description: Likert Scale. Time: 15 minutes
Description: When the mask is removed, participants will be asked about willingness to use this mask compared to N-95 masks using a 5-point Likert scale from 'Very unlikely' to 'Very likely'.Measure: Willingness of usage. Description: Likert Scale. Time: after 15 minutes
Data processed on December 13, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports